Search…

HIV and immunotherapy drug demand strong, GlaxoSmithKline (GSK.US) raises full-year performance guidance.

30/10/2025

Zhitan Financial APP has learned that due to the growth in demand for HIV and immunological drugs, GlaxoSmithKline (GSK.US) has raised its full-year profit and sales expectations. The financial report shows that the company's Q3 revenue reached 8.55 billion pounds, a year-on-year increase of 4.9%, exceeding expectations by 300 million pounds; excluding certain items, earnings per share increased by 11% to 0.55 pounds, surpassing analysts' previous expectations of 0.47 pounds.

Latest

1 m ago

Food producer Yili International fell 4.3% at the end of Wednesday, after the company announced its third quarter performance, with revenue of $9.744 billion, a year-on-year increase of 5.9%, higher than market expectations. However, its organic growth slowed to 3.4% from 5.6% in the second quarter, mainly due to a 4.6% decrease in sales/combinations. Adjusted earnings per share were $0.73, a 23% decrease year-on-year. What's even more concerning for investors is that the gross margin is 30.4%, a 10 percentage point decrease year-on-year, failing to meet market expectations.

4 m ago

Medical insurance company Company X's stock soared 12.7% at the close of trading on Wednesday. Prior to this, the company's third quarter financial report revealed unexpectedly profitable results. Adjusted for certain items, Company X's earnings per share for the third quarter were 50 cents, surpassing analysts' expectations of a loss of 14 cents per share. This impressive performance was mainly due to lower tax rates.

5 m ago

Sudan Rapid Support Forces announce investigation into the killing of civilians in Fashir.

7 m ago

"The new bond king" Gundlach: will reduce the proportion of gold in the investment portfolio to about 10%.

8 m ago

"New Bond King" Gundlach: There is a 50% possibility of a rate cut in December.

See all latest